Accueil Ernstrade Bourse Actualite Stock

plus500
 
EURONEXT BRUSSELS

Ablynx, a biopharmaceutical company with headquarters in Ghent, Belgium, is engaged in the discovery and development of Nanobodies® to treat a range of serious human diseases. Nanobodies® are a novel class of antibody-derived therapeutic proteins. Because of their small size, unique structure and extreme stability, Nanobodies® combine the advantages of conventional antibody therapeutics with the key features of small-molecule drugs.
The power of Ablynx's discovery platform has resulted in a Nanobody® development candidate. Ablynx’s lead programme, 
ALX-0081, became the first ever single domain antibody to enter clinical trials and Ablynx reported the final positive results from its Phase I study in December 2007. Following these positive results, Ablynx has initiated a Phase Ib multiple-dose study in May 2008, directly in the target patient population rather than healthy volunteers for ALX-0081.

http://www.ablynx.com


27.02.2013 ABLYNX ANNOUNCES 2012 FULL YEAR RESULTS

25.08.2011 ABLYNX ANNOUNCES HALF YEAR 2011 RESULTS 

22.02.2010 ABLYNX ANNOUNCES 2010 FULL YEAR RESULTS
REGULATED INFORMATION
Five Nanobody-based products in clinical trials; three in Phase II and two in Phase I
Good progress in preparations for three new Phase I trials to start in 2011
Excellent financial position with €115.9 million in cash, cash equivalents, restricted cash and short term investments
€31.4 million in revenues
Net cash burn, excluding the Secondary Public Offering, well managed at just  €23.6 million 
GHENT, Belgium, 22 February 2011 - Ablynx [Euronext Brussels: ABLX] today announced its consolidated results for 2010, which have been prepared in accordance with IFRS as adopted by the European Union, and highlighted the developments in its product pipeline and partnerships.
In 2010, revenues increased by 6% to €31.4 million (2009: €29.7 million), primarily driven by milestone payments from Boehringer Ingelheim. Total research and development costs increased to €48.5 million (2009: €42.8 million), in line with the increasing number of pre-clinical and clinical development candidates. General and administrative expenses remained well under control at €8.9 million (2009:  €9.0 million). The loss from continuing operations, before tax and net finance income, increased to €25.9 million (2009: €22.2 million). The net loss for the period was €24.5 million (2009: €20.0 million). In part thanks to the successful Secondary Public Offering (SPO) in March 2010, which raised €50 million, the Company ended the year with €115.9 million in cash, cash equivalents, restricted cash and short term investments. 
 

ABLYNX ANNOUNCES WEBCAST OF ITS PRESENTATION AT THE 29TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE 
GHENT, Belgium, 4 January 2011 - Ablynx [Euronext Brussels: ABLX] today announced that it will webcast its corporate presentation at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, 11 January 2011 at 11.00 a.m. PST / 08.00 p.m. CET.
The presentation, followed by a Q&A, will be hosted by Dr Edwin Moses, CEO and Chairman of Ablynx. The presentation will be webcast live and may be accessed on the home page of Ablynx's website at www.ablynx.com. A replay of the webcast will also be available on the Company's website for 30 days following the presentation.
To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast. 

ABLYNX RECEIVES FURTHER MILESTONE PAYMENTS OF €3 MILLION AS PART OF ITS STRATEGIC ALLIANCE WITH BOEHRINGER INGELHEIM 
GHENT, Belgium, 12 November 2010 - Ablynx [Euronext Brussels: ABLX] today announced that it will receive further milestone payments totalling €3 million from Boehringer Ingelheim, triggered as part of its strategic alliance for the development and commercialisation of Nanobodies®. Ablynx has now earned a total of €15 million in milestone payments as part of this agreement.
Ablynx and Boehringer Ingelheim entered into an agreement in September 2007 to collaborate on the discovery, development and commercialisation of up to 10 different Nanobody therapeutics across a range of areas including for example immunology, oncology and respiratory diseases. The agreement would allow potential milestone payments of up to €125 million for each Nanobody developed as well as undisclosed royalties to Ablynx. Boehringer Ingelheim is exclusively responsible for the development, manufacture and commercialisation of any products resulting from the collaboration. Ablynx retains certain co-promotion rights in Europe.
Dr Edwin Moses, CEO and Chairman of Ablynx, commented: "This is the fifth set of €3 million milestone payments we have achieved since the start of the collaboration in September 2007. We believe this further demonstrates the potential of the Nanobody technology in complex target areas. We look forward to seeing the collaborative programmes advancing further in development."

ABLYNX ANNOUNCES HALF YEAR RESULTS FOR 2010 
GHENT, Belgium, 25 August 2010 - Ablynx [Euronext Brussels: ABLX] announced today its results for the six month period ending 30 June 2010, which have been prepared in accordance with the IAS 34 'Interim Financial Reporting' as adopted by the European Union. 
H1 2010 Highlights
€121.3 million in cash, cash equivalents and other short term investments at 30 June 2010 (2009: €101.8 million)
Revenues of €10.1 million (2009: €11.9 million)
Successfully completed a Secondary Public Offering (SPO), raising gross proceeds of €50.0 million 
Received a €2.0 million milestone payment from Boehringer Ingelheim on selection of the first Nanobody® lead candidate for the treatment of Alzheimer's disease 
Awarded €1.2 million in grant funding from IWT to accelerate the development of ALX-0061, an anti-IL-6R Nanobody for inflammatory disease
Completed the recruitment of the Phase I study for ALX-0141 (anti-RANKL)
Selected a new pre-clinical development candidate, ALX-0651, which targets the GPCR CXCR4, for use in patients requiring hematopoietic stem cell mobilization
Selected ALX-0171, an anti-RSV Nanobody, for pre-clinical development for the treatment of respiratory syncytial virus (RSV) infections
Reported the successful generation of functional Nanobodies against an ion channel
Announced new data on pulmonary to systemic delivery and needle-free administration of Nanobodies
Extended for another year the research collaboration which forms part of the license agreement for anti-TNF-alpha Nanobodies with Pfizer
Successfully opposed a half-life extension patent which had been granted to Domantis (a member of the GSK group) resulting in this patent being revoked in full
Reached a settlement with reMYND concerning a collaboration agreement dispute
Won the European Mediscience Award for the second year in a row for 'Best Technology' 
 Increased staff to over 246 people by period end
Moved to a new 8,000 m2 R&D facility 
For more information, please contact Ablynx:
Dr. Edwin Moses
Chairman and CEO 
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e: edwin.moses@ablynx.com
Eva-Lotta Allan
Chief Business Officer
t: +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
e: eva-lotta.allan@ablynx.com
 Wim Ottevaere
Chief Financial Officer
t:  +32 (0)9 262 00 08
e: wim.ottevaere@ablynx.com


Copyright  2017  Ernstrade.com